View on Pubmed.gov 15528141 | View on doi.org 10.1016/j.bcmd....
IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
- University Hospital Frankfurt, Paediatric Haematology and Oncology, Frankfurt, Germany. koehl@em.uni-frankfurt.de
Abstract
Natural killer (NK) cells are thought to be of benefit in HLA-mismatched hematopoietic transplantation (H-SCT). Therefore, we developed a protocol for clinical-use expansion of highly enriched and IL-2-stimulated NK cells. Purification of unstimulated leukaphereses by a two-step T cell depletion with a final CD56 enrichment procedure leads to a mean purity of 95% CD56(+)CD3- NK cells with a four- to five-log depletion of T cells. So far, three pediatric patients with multiply relapsed acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) were treated with repeated transfusions post-H-SCT. Directed killer immunoglobulin-like receptor (KIR) mismatches were demonstrated in all three cases. Although all patients showed blast persistence at the time of transplant, they reached complete remission and complete donor chimerism within 1 month post-H-SCT. NK cell therapy was tolerated well without graft-versus-host disease (GvHD) induction or other adverse events. The AML patient died of early relapse on day +80, while the ALL patients died of thrombotic-thrombocytopenic purpura and atypical viral pneumonia on days +45 and +152, respectively. This initial trial showed the feasibility of good manufacturing practice (GMP)-compliant NK cell isolation and expansion for clinical applications. We now launch a clinical phase I trial with activated NK cells post-H-SCT.
References
Cited by 135 citations (total)
Journal Article
Effect of allogeneic blood transfusion on levels of IL-6 and sIL-R2 in peripheral blood of children with acute lymphocytic leukemia.
Electronic publication date July 3, 2018
Hui Zhao [...] Fang Zhao et al.
Effect of allogeneic blood transfusion on the expression of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in peripheral blood of...
Journal Article Research Support, Non-U.S. Gov't Review
Current Status of Gene Engineering Cell Therapeutics.
Electronic publication date February 21, 2018
Aurore Saudemont [...] Timothy Clay et al.
manipulations of autologous patient's cells or gene-engineered cell therapeutics have allowed the development of cell and gene therapy approaches to...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •